Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

3.23
-0.0700-2.12%
Volume:235.19K
Turnover:750.08K
Market Cap:368.22M
PE:-2.43
High:3.34
Open:3.32
Low:3.13
Close:3.30
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:67.93M
Volume Ratio:0.80
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:1.14
PE(LYR):-2.31

Loading ...

BTIG Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

RBC Capital Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

TIPRANKS
·
May 12

Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances

TIPRANKS
·
May 12

Perspective Therapeutics Q1 net loss widens as grant revenue drops

Reuters
·
May 12

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate

Benzinga Earnings
·
May 12

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

THOMSON REUTERS
·
May 12

Perspective Therapeutics Q1 EPS USD -0.25

THOMSON REUTERS
·
May 12

Perspective Therapeutics (CATX) Receives a Buy from JonesTrading

TIPRANKS
·
May 07

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
May 05

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
May 05

Perspective Therapeutics (CATX) Receives a Buy from Truist Financial

TIPRANKS
·
May 05

Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update

TIPRANKS
·
May 05

Perspective Therapeutics to host analyst event on strategy, enabling technology, pipeline

Reuters
·
Apr 24

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

GlobeNewswire
·
Apr 24

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX)

TIPRANKS
·
Apr 20

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Maravai Lifesciences Holdings (MRVI) and LENZ Therapeutics (LENZ)

TIPRANKS
·
Apr 20

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Apr 20

Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 20

Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data

TIPRANKS
·
Apr 20